Health News (Reuters)

EU approves fifth copy of AbbVie's $18 billion drug Humira

Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.

Baby-boomers expect kids to care for them when they're sick

(Reuters Health) - Three in four baby-boomers with children expect one of their kids to help care for them when their health fails in old age and they don't have a spouse who can do this, a UK study suggests.

Low-carb diet better when it includes more vegetables, nuts

(Reuters Health) - People who cut back on carbohydrates may end up increasing their risk of premature death if they load their plates with meat and cheese instead of vegetables and nuts, a U.S. study suggests.

Zimbabwe seeks $35 million to fight cholera outbreak

Zimbabwe is appealing to individual citizens and local companies for $35 million to help fight a cholera outbreak that has killed 31 and infected more than 5,000, the finance minister said.

AstraZeneca plots China robot offensive to counter price cuts

With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.

Clovis Oncology, execs to pay $20 million to settle SEC charges

U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

U.S. judge dismisses concussions lawsuits against World Wrestling

A federal judge has dismissed lawsuits by dozens of former professional wrestlers who accused World Wrestling Entertainment Inc of failing to protect them from concussions and other head trauma, including chronic traumatic encephalopathy (CTE).

GSK grabs new drug development head from Boehringer

GlaxoSmithKline has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research strategy, a spokesman for the British group said on Tuesday.

Pages